Cargando…
Randomized phase III study of gemcitabine, cisplatin plus S‐1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401‐ MITSUBA)
BACKGROUND: Gemcitabine/cisplatin (GC) combination therapy has been the standard palliative chemotherapy for patients with advanced biliary tract cancer (BTC). No randomized clinical trials have been able to demonstrate the survival benefit over GC during the past decade. In our previous phase II tr...
Autores principales: | Ioka, Tatsuya, Kanai, Masashi, Kobayashi, Shogo, Sakai, Daisuke, Eguchi, Hidetoshi, Baba, Hideo, Seo, Satoru, Taketomi, Akinobu, Takayama, Tadatoshi, Yamaue, Hiroki, Takahashi, Masahiro, Sho, Masayuki, Kamei, Keiko, Fujimoto, Jiro, Toyoda, Masanori, Shimizu, Junzo, Goto, Takuma, Shindo, Yoshitaro, Yoshimura, Kenichi, Hatano, Etsuro, Nagano, Hiroaki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10086809/ https://www.ncbi.nlm.nih.gov/pubmed/35900311 http://dx.doi.org/10.1002/jhbp.1219 |
Ejemplares similares
-
Clinical outcomes of second‑line chemotherapy after gemcitabine and cisplatin plus S‑1 treatment for patients with advanced biliary tract cancer in the KHBO1401‑3A study
por: Shindo, Yoshitaro, et al.
Publicado: (2023) -
Pharmacokinetic Study of Adjuvant Gemcitabine Therapy for Biliary Tract Cancer following Major Hepatectomy (KHBO1101)
por: Fujiwara, Yutaka, et al.
Publicado: (2015) -
Phase I study of adjuvant chemotherapy with gemcitabine plus cisplatin in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1004)
por: Toyoda, Masanori, et al.
Publicado: (2014) -
Comparison of full-dose gemcitabine/cisplatin, dose-reduced gemcitabine/cisplatin, and gemcitabine/carboplatin in real-world patients with advanced urothelial carcinoma
por: Sugimoto, Kazuma, et al.
Publicado: (2022) -
Cisplatin/gemcitabine: Pancytopenia: case report
Publicado: (2021)